🇪🇺 Dipeptidyl-Peptidase IV Inhibitors in European Union

EMA authorised Dipeptidyl-Peptidase IV Inhibitors on 19 July 2012

Marketing authorisation

EMA — authorised 19 July 2012

  • Application: EMEA/H/C/002279
  • Marketing authorisation holder: Boehringer Ingelheim International GmbH
  • Local brand name: Jentadueto
  • Indication: Treatment of adult patients with type-2 diabetes mellitus: Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin. Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
  • Status: approved

Read official source →

Other Diabetes approved in European Union

Frequently asked questions

Is Dipeptidyl-Peptidase IV Inhibitors approved in European Union?

Yes. EMA authorised it on 19 July 2012.

Who is the marketing authorisation holder for Dipeptidyl-Peptidase IV Inhibitors in European Union?

Boehringer Ingelheim International GmbH holds the EU marketing authorisation.